Home › Ulcerative Colitis › Indiana
Ulcerative Colitis clinical trials in Indiana
9 studies for Ulcerative Colitis are looking for participants at sites in Indiana.
Cities in Indiana
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- IU Health University Hospital, Indianapolis
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 25, 2026 · NCT07196748A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Riley Hospital for Children, Indianapolis
RecruitingPhase 3
Ages 3 and older · All sexes · Updated Sep 25, 2026 · NCT06663332A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
- Local Institution - 0100, Indianapolis
RecruitingPhase 2/3
Ages 2 to 17 · All sexes · Updated Sep 24, 2026 · NCT05076175Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Indiana University Health University Hospital, Indianapolis
- Gastroenterology Health Partners, New Albany
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT06937086LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
- Gastroenterology Health Partners, New Albany
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07415044LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
- Gastroenterology Health Partners, New Albany
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07186101A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Gastroenterology Health Partners, PLLC - New Albany - Site Number: 8400100, New Albany
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 15, 2026 · NCT07185009An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Gastroenterology Health Partners, PLLC - Site Number: 8400100, New Albany
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Aug 20, 2026 · NCT07184996Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
- Bausch Health Site 003, Indianapolis
RecruitingPhase 4
Ages 5 to 17 · All sexes · Updated Sep 16, 2025 · NCT04314375From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.